Head-To-Head Analysis: AC Immune SA


AC Immune SA and Alnylam Pharmaceuticals are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership. AC Immune SA presently has a consensus price target of $21.67, suggesting a potential upside of 86.62%.



from Biotech News